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Introduction
Autophagy is an important degradative mechanism that delivers 
select cytoplasmic components into the lysosome for recycling 
purposes (Mizushima and Komatsu, 2011). Activation of auto-
phagy promotes cell survival under adverse conditions, such as 
during metabolic stress. Accordingly, inhibition of autophagy in 
cancer cells has been proposed as a potential therapeutic strat-
egy (White, 2012). However, because inhibition of autophagy 
itself is not sufficient to induce cancer cell death, the mecha-
nism and means by which to sensitize cancer cells to autophagy 
inhibition remain to be identified.
Chaperone-mediated autophagy (CMA) delivers select pro-
teins with a pentapeptide CMA-targeting motif into the lysosome 
mediated by their binding with the chaperone Hsc70 and the in-
teraction with lysosome-associated membrane protein type 2A 
(Lamp-2A), a lysosomal membrane receptor (Kaushik and Cu-
ervo, 2012). We have shown that autophagy inhibition by a small 
molecule inhibitor, spautin-1, can lead to the activation of CMA to 
mediate the degradation of mutant p53 under nutrient deprivation 
conditions (Vakifahmetoglu-Norberg et al., 2013). Furthermore, 
we showed that CMA activation induces the death of nonpro-
liferating quiescent cancer cells, while normal cells are spared 
(Vakifahmetoglu-Norberg et al., 2013). These findings raise the 
intriguing possibility of inducing CMA activation as a potential 
anticancer therapy. However, because maximal CMA activation 
requires a combination of nutritional stress and a blockade of au-
tophagy, the therapeutic feasibility of this strategy is unclear.
Receptor tyrosine kinases (RTKs) are critical mediators of 
cell growth and survival. Abnormal activation of the PI3K–Akt 
pathway is common in a wide range of cancers with mutated 
and dysregulated RTKs. Fms-like tyrosine kinase 3 (FLT3), a 
member of the class-III RTK family, is a validated target for the 
treatment of acute myeloid leukemia (AML; Kayser and Levis, 
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2014). Quizartinib (AC220), a selective and potent inhibitor of 
FLT3, is currently under clinical trial against AML with activat-
ing FLT3 mutations (Zarrinkar et al., 2009). However, the value 
of targeting FLT3 beyond AML has not been well explored.
Hexokinase II (HK2) is a key enzyme involved in catalyz-
ing the first committed step of glucose metabolism, regulated by 
growth factor signaling (Shaw and Cantley, 2006; Nederlof et 
al., 2014). It has been recognized as an oncogenic kinase, as it is 
required for tumor initiation and maintenance of multiple types 
of tumors (Patra et al., 2013). Consequently, inhibition of HK2 
has been proposed as a potential anticancer strategy. However, no 
method has yet been described to reduce HK2 levels in cancer cells.
In this study, we investigated the mechanism that sensitizes 
cancer cells to autophagy inhibition. We show that inhibition of 
FLT3 in nonhematopoietic cancers increases their sensitivity to 
autophagy inhibition under conditions where they are normally 
resistant. Simultaneous inhibition of FLT3 and autophagy leads 
to excessive activation of CMA and cancer cell death under nor-
mal nutritional conditions. We characterized targets of the CMA 
pathway using an unbiased proteomic approach and identified 
HK2, a key glycolytic enzyme, as a CMA substrate. Impor-
tantly, we provide a new mechanism by which excessive activa-
tion of CMA may be exploited as a method to eliminate cancer 
cells by inducing metabolic catastrophe and delineate a novel 
strategy to promote the degradation of HK2 in cancer cells.
Results and discussion
FLT3 inhibitor AC220 (Quizartinib) 
sensitizes nonconfluent cancer cells  
to spautins under normal nutritional 
conditions
Our medicinal chemistry campaign to improve the original au-
tophagy inhibitor spautin-1 (C43) synthesized and tested the 
biological activities of >700 derivatives (unpublished data) and 
led to the identification of A70, which inhibits autophagy with 
an IC50 of 0.076 µM (Fig. S1 A). Similar to the actions of C43, 
the treatment with A70 induces the death of cancer cells under 
glucose-free as well as confluent conditions (Fig. S1 B); impor-
tantly, A70 was able to induce cancer cell death at significantly 
lower concentrations than that of C43 (Fig. S1 C).
Because both C43 and A70 induce cell death only in glu-
cose-free or confluent conditions, we sought to identify small 
molecules that could mimic these stressful cellular states and 
thus, in combination with spautins, would eliminate cancer cells 
regardless of growth condition. We established a high-through-
put screen using ovarian carcinoma-derived ES2 cells, which 
display resistance to C43 or A70 under normal proliferating and 
full nutritional conditions (Fig. S1 B; Vakifahmetoglu-Norberg 
et al., 2013). We screened 8,248 compounds from the ICCB 
Known Bioactives Library, and identified 115 hits with poten-
tial minimal toxicity when treated alone but that significantly 
promoted the loss of cell viability in the presence of A70 in both 
ES2 and Sum159 cells (unpublished data).
This analysis identified Quizartinib (AC220), an RTK in-
hibitor, as the most effective sensitizer of the autophagy inhib-
itors A70 or C43. AC220 significantly increased the efficacy of 
A70 and C43 in inducing cell death of ES2 and Sum159 cells 
in a dose-dependent manner under normal growth conditions 
(Fig. 1, A and B), whereas single compound treatment had no 
or little effect on the cell survival. Similar results were observed 
in Bcap-37, MCF-7, HCT116, and MDA-MB-435 cancer cells 
(Fig.  1  C and S1 D). In contrast to the cancer cell lines an-
alyzed, a normal cell line derived from the MDCK was not 
significantly affected by the combination treatment of C43 and 
AC220 (Fig. 1 C). In addition, we tested the sensitivity for sin-
gle or combination treatments of C43 and AC220 on three AML 
cell lines (Fig. 1 D). While only Molm-14, an AML cell line 
carrying FLT3/ITD mutation, died with AC220 alone, the com-
bination treatment of AC220 and C43 significantly reduced the 
cell viability of HEL and OCI-AML3 AML cells, which have 
no FLT3 mutation (Fig. 1 D). Western blot (WB) analysis of the 
level of FLT3 showed that the total and phospho-FLT3 levels 
are expressed in all cell lines used in this study (Fig. S1 E).
Furthermore, while other RTK inhibitors, such as Lapa-
tinib and Nilotinib, could also promote the death of ES2 cells 
in the presence of C43, these compounds induced substan-
tial death even when treated alone (Fig. S1 F), which sug-
gests that AC220 provides the chemical means to selectively 
sensitize cancer cells to autophagy inhibition under normal 
growth conditions. Because the susceptibility of both C43 and 
A70 is sensitized by the effect of AC220, we used both com-
pounds in subsequent experiments.
Consistent with the inhibition of FLT3, silencing the FLT3 
expression mimicked the effect of AC220: knockdown of FLT3 
had no effect on the survival of ES2 cells, whereas it markedly 
increased the cell death sensitivity to spautins and significantly 
reduced cell viability in combination with either C43 or A70 
(Fig. 1 E). Thus, inhibition of FLT3 by AC220 or its knockdown 
is sufficient to enhance the effect of spautins to induce the death 
of cancer cells. Notably, we detected reduced levels of FLT3 
autophosphorylation in ES2 cells under confluence and in glu-
cose-free conditions compared with that of normal culture con-
dition (Fig. 1 F), which could potentiate the effect of spautins. 
Accordingly, the application of AC220 in normal proliferating 
culture conditions mimicked FLT3 inhibition observed under 
metabolic stress conditions, suggesting that the FLT3 signaling 
pathway is a critical sensor and regulator of cellular nutritional 
states. To further assess the contribution of autophagy inhibi-
tion in combination of AC220, we performed siRNA-mediated 
knockdown of ATG7, an essential autophagy-related gene, in 
ES2 cells, which led to a marked decreased in viability of ES2 
cells in combination with AC220 (Fig. 1 G).
C43 treatment of ES2 cells in confluence leads to the 
degradation of multiple deubiquitinating enzymes through the 
proteasomal pathway (Liu et al., 2011; Vakifahmetoglu-Nor-
berg et al., 2013). To test if AC220 treatment mimics cellular 
confluence, we treated nonconfluent cells ES2 and HCT116 
with AC220 and C43 and found that the levels of endogenous 
Beclin1, USP10, and USP13 also progressively decreased in a 
concentration-dependent manner. The reduction of the levels 
of these proteins was strongly correlated with the inhibition of 
FLT3 autophosphorylation by AC220 (Figs. 1 H and S1 G). In 
contrast, the treatment of C43 or AC220 alone had no effect 
on USP10, USP13, or Beclin1 protein levels under noncon-
fluent conditions (Fig. 1 H).
FLT3 inhibition suppresses glycolysis and 
induces macroautophagy
FLT3 has a well-established role in regulating the survival and 
proliferation of hematopoietic stem/progenitor cells. Activation 
of FLT3 kinase leads to signal transduction of several down-
stream pathways, such as the PI3K–AKT pathway and the RAS/
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Figure 1. FLT3 inhibition sensitized nonconfluent cancer cells to spautins. (A) Cell viability (%) of ES2 cells treated with increasing concentrations of AC220 
and/or A70 for 24 h. (B) Cell viability (%) and cell death (fold) of ES2 and Sum159 cells treated with AC220 and/or C43 or A70 for 24 h. (C and D) 
Cell viability (%) of Bcap-37, MCF-7, and MDCK cells (C) and of OCI-AML3, HEL, and Molm-14 cells (D), treated with AC220 and C43 for 24 h. (E) Cell 
viability (%) of scramble (SCR) or FLT3 siRNA–transfected ES2 cells treated with C43 for 24 h. WB confirmed the FLT3 siRNA efficiency. (F) Phospho- and 
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RAF/MEK/ERK cascade (Parcells et al., 2006). To uncover the 
mechanism by which AC220 conveys sensitivity toward inhibi-
tion of autophagy, we explored the downstream consequences 
of inhibiting the FLT3 pathway in nonhematopoietic lineage–
derived cells, such as breast and ovarian carcinoma cells. To-
ward this end, we assessed cellular proliferation and found that 
AC220 can suppress the proliferation of ES2 and Sum159 cells 
without inducing cell death (Fig.  2  A). AC220-treated cells 
also demonstrated a time-dependent reduction of Akt phos-
phorylation on Ser473, a marker for its activation (Correa et 
al., 2012; Fig. 2 A). Treatment with C43 alone induced a slight 
increase in Akt Ser473 phosphorylation, which was inhibited 
by AC220 (Fig. 2 B, left). Notably, Akt Ser473 phosphorylation 
was inhibited in ES2 cells cultured under confluent conditions 
(Fig. 2 B, right), suggesting that inhibition of Akt activation by 
AC220 might contribute in part to its sensitization to spautins in 
nonconfluent cell cultures.
Metabolic reprogramming as a result of oncogenic signal-
ing alteration plays an important role in regulating energy and 
biomaterial production in cancer cells. However, the role of FLT3 
in glucose metabolism is not well appreciated. Given that Akt has 
a crucial role in regulating glucose metabolism (Elstrom et al., 
2004), we measured lactate production in nonconfluent cells in 
the presence of AC220 or in combination with C43. In both ES2 
and Sum159 cells, AC220 was able to markedly reduce lactate 
production and significantly block glucose uptake, which was 
further reduced in the presence of C43 (Fig. 2 C and Fig. S2 A). 
Our investigation of the effect of AC220 and C43 on the extra-
cellular acidification rate (ECAR), which measures the rate of 
lactate production from glycolysis, showed that while C43 did 
not affect glycolysis, both glycolytic function and the glycolytic 
capacity were significantly suppressed by AC220 treatment and 
further reduced in combination with C43 (Fig. 2 D). Consistently, 
ECAR analysis on Molm-14 and OCI-AML3 cells revealed that 
the glycolysis and glycolytic capacity were markedly decreased 
by both single AC220 and combination treatment with C43 in 
AML cell lines similar to that of ES2 ovarian cancer cells (Figs. 
2 E and S2 B). We next characterized the impact of AC220 and 
C43 on the cellular glycolytic state in ES2 cells by glucose flux 
analysis. This analysis revealed that all quantitatively validated 
individual intracellular metabolic products of glucose from gly-
colysis were significantly suppressed by AC220 treatment and 
further reduced in combination with C43 (Fig. 2 F).
Collectively, our data from ECAR, glucose uptake, and 
flux analyses demonstrate that AC220 significantly inhibits 
glycolysis, suggesting that FLT3 may have a previously unap-
preciated role in regulating glucose uptake and glycolysis in 
cancer cells beyond AML, and that the FLT3 inhibitor AC220 
may be considered for the treatment of non-AML related can-
cers in combination therapies.
Consistent with blockage of glucose metabolism, treat-
ment of AC220 increased the levels of LC3-II, which is in-
dicative of autophagy activation, in ES2 and Sum159 cancer 
cells (Figs. 2 G and S2 C). As expected, C43 or A70 were able 
to attenuate the autophagy up-regulation induced by AC220 
(Fig.  2  G). In contrast, although Lapatinib or Nilotinib were 
quite effective in inducing ES2 cell death (Fig. S1 F), their effect 
on glucose uptake was significantly less compared with that of 
AC220 (Fig. S2 D). Furthermore, increased LC3-II levels were 
only detected in Lapatinib-treated cells, whereas no change was 
found upon Nilotinib treatment. Autophosphorylation of FLT3 
was not reduced by either Lapatinib or Nilotinib (Fig. S2 D). 
Consistent with the importance of FLT3 in mediating cell death 
in this context, dual suppression of Akt and PI3K, the down-
stream mediators of FLT3, elicited robust cell death when com-
bined with C43 treatment (Fig. S2 E). Additionally, a significant 
autophagy induction was not detected in the presence of PI3K 
inhibitors (LY294002 or Wortmannin) or Akt inhibitor MK2206 
alone (Fig. S2 F). Collectively, these findings indicate that FLT3 
has a role as an important sensor of cellular nutritional state in 
cancer cells beyond AML and that its inhibition promotes met-
abolic stress and strong dependency on autophagy for survival.
Combinatory inhibition of FLT3 and 
autophagy activates CMA
C43 treatment under nutritional limiting or confluent conditions 
significantly accelerates the activation of CMA, which leads to 
the degradation of mutant p53 (Vakifahmetoglu-Norberg et al., 
2013). We found that the combination of AC220 with either C43 
or A70 treatment can similarly enhance the degradation of mu-
tant p53 proteins in nonconfluent conditions in ES2 cells (Figs. 
3 A and S3 A), whereas no significant change of p53 mRNA 
levels were observed (Fig. S3 B). The level of degradation of 
mutant p53 upon AC220 and C43 was comparable with the 
effect of C43 treatment observed in confluent conditions (Fig. 
S3 C). Significant reduction of mutant p53 in MDA-MB-231, 
Sum159, and MDA-MB-435 cell lines was also observed upon 
combination treatment (Fig.  3  A, bottom). In contrast, single 
treatment of C43, A70, or AC220 had no effect on the mutant 
p53 protein levels under nonconfluent conditions (Figs. 3 A and 
S3, A and C). The knockdown of FLT3 levels did not affect 
the levels of mutant p53 protein, but subsequent treatment with 
C43 induced degradation of mutant p53 (Fig.  3  B). Further-
more, while the proteasome inhibitor MG132 did not show an 
effect on the levels of mutant p53 protein, lysosomal inhibitor 
chloroquine (ClQ) attenuated AC220 and C43 combination-in-
duced mutant p53 degradation in ES2 cells (Fig. 3 C), suggest-
ing that mutant p53 is degraded through the lysosomal pathway. 
The reduction in mutant p53 levels upon AC220 and C43 treat-
ment was accompanied by increased degradation of GAPDH 
and IκB, two known substrates of CMA (Aniento et al., 1993; 
Cuervo et al., 1998; Fig. 3 D). Additionally, siRNA-mediated 
knockdown of either Hsc70 or Lamp2A, the key mediators of 
CMA, in ES2 cells attenuated mutant p53 depletion induced by 
the combination treatment (Fig. 3 E), demonstrating that inhi-
bition of FLT3 by AC220 in combination with C43 activates 
CMA in proliferating cells under nutritionally rich conditions.
Next, we explored the mechanism of cell death induced 
by the combination treatment of AC220 and C43. While sin-
gle compound treatment had only a minimal effect, the combi-
total FLT3 protein levels of ES2 cells cultured in confluent (Conf), nonconfluent (Non-C), or glucose-free (Gluc free) conditions, treated with AC220 for 24 h.  
(G) Cell viability (%) of scramble (SCR) or ATG7 siRNA–transfected ES2 cells treated with AC220 or C43 for 24 h. (H) WB of indicated proteins in ES2 
and HCT116 cells treated with increasing concentrations of AC220 and/or C43 for 24 h. Anti–α-tubulin was used as a loading control. Cells were treated 
with 0.1% DMSO (control: vehicle) or 1 µM AC220 and 10 µM C43, unless otherwise stated. In all the experiments, treatment groups were compared 
with control group, unless otherwise indicated. Error bars indicate ±SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 2. Treatment with AC220 (Quizartinib) reduces glycolysis and induces macroautophagy. (A) Proliferation capacity (%) of ES2 and Sum159 cells 
treated with AC220 for 16 h. Phospho- and total Akt levels of ES2 and Sum159 cells treated with AC220 up to 24 h. (B) WB of phospho- and total Akt lev-
els of ES2 cells treated with AC220 and C43 (left), or C43 alone in confluent (Conf) or nonconfluent (Non-C) conditions (right) for 24 h. (C) Relative change 
JCB • Volume 210 • NumBer 5 • 2015710
nation treatment led to a significant reduction of cellular ATP 
levels as well as increased Annexin V positivity and propidium 
iodide (PI) uptake (Fig. 3, F and G). This was not inhibited by 
either zVAD.fmk, a pan caspase inhibitor, or 7-Cl-O-Nec-1 
(7N-1), a RIPK1 inhibitor (Degterev et al., 2005). Moreover, 
no caspase-3 or PARP cleavage was detectable after C43 and 
AC220 combination treatment, in contrast to the treatment of 
staurosporine (STS; Fig. 3 G). Instead, siRNA-mediated knock-
down of Hsc70 or Lamp2A significantly suppressed the cell 
death (Fig.  3  H). These data suggest that the CMA pathway, 
at least in part, mediates the cell death observed after C43 and 
AC220 combination treatment.
We observed a major drop in the levels of cellular ATP upon 
CMA activation induced by combination treatment of AC220 and 
C43 (Fig. 4 A). The metabolic dysfunction upon AC220 and C43 
treatment was also indicated by the significantly elevated cellular 
ratios of ADP/ATP and NAD+/NADH (Fig. 4, B and C). This 
prompted us to perform additional metabolic analysis. Notably, 
we found that single treatment with AC220, which reduced gly-
colysis (Fig. 2 D), did not drastically affect cellular ATP levels 
(Fig. 4 B) or mitochondrial oxygen consumption rates (OCRs; 
Fig. 4 D). Thus, single treatment with either AC220 or C43 had 
a minimal effect on the cellular ATP levels (Fig. 4 B). Most cells 
demonstrate plasticity in their ability to generate ATP from ei-
ther glycolysis or mitochondrial respiration in response to altered 
cellular metabolism, whereby blockage of one metabolic path-
way rapidly shifts cells to generate ATP from the other. Consis-
tently, we found that glutamine uptake was stimulated by AC220 
treatment (Fig. 4 E), which might provide an alternative energy 
source for maintaining cellular ATP levels. Furthermore, AC220 
showed no synergy with inhibitors of fatty acid oxidation (FAO), 
such as Etomoxir or T0070907, but synergized with oligomycin 
or rotenone, which disrupt mitochondrial respiration (Fig. 4 F). 
Thus, cancer cells treated with AC220 are in metabolic stress due 
to inhibition of glycolysis but survive because of concomitant 
sustained oxidative phosphorylation and autophagy activation. 
Strikingly, the combination treatment of AC220 and C43 abol-
ished the compensatory metabolism and inhibited glutamine up-
take (Fig. 4 E). Therefore, we reasoned that the significant effect 
of combination treatment on metabolism is due to the concerted 
actions of both compounds, which induce a rapid collapse in ATP 
level and lead to cell death via metabolic catastrophe.
Consistent with the importance of CMA in cell death in-
duced by AC220 and C43, measurement of the mitochondrial 
OCRs of intact cultured cells after combination treatment re-
vealed a significant reduction in the ATP-coupled OCR, which 
was dramatically rescued in cells with a reduced CMA capac-
ity after siRNA-mediated knockdown of Hsc70 or Lamp-2A 
(Fig. 4 G). Hsc70 siRNA-mediated rescue of ATP levels was 
abolished by sublethal concentrations of oligomycin, sup-
porting the role of mitochondrial respiration (Fig. S3 D). Fur-
thermore, siRNA-mediated knockdown of Hsc70 or Lamp2A 
significantly reversed the ATP levels under combination treat-
ment (Fig. 4 A). These results suggest that CMA may be ac-
tivated to mediate cell death after depriving cells of multiple 
cellular bioenergy sources to lead to a metabolic catastrophe 
with the combination of AC220 and spautins. Our findings fur-
ther suggest that a combinatorial inhibition of both FLT3 and 
autophagy provides a method to effectively inhibit adapted me-
tabolism in cancer cells through the activation of CMA.
CMA promotes the degradation of HK2 
and leads to metabolic catastrophe
To gain further insight into the role of CMA in the death of can-
cer cells, we performed an unbiased quantitative proteomic ap-
proach to characterize the proteins that are specifically degraded 
via the CMA pathway. To eliminate the contribution from the 
proteasome, the samples were treated with MG132, which had 
no effect on the degradation of mutant p53 (Fig. 5 A). We used 
tandem mass tag (TMT)-based quantitative mass spectrome-
try to analyze protein level changes in the cytosolic fractions 
of ES2 cells treated with a combination of C43 and AC220. 
From 2,051 proteins analyzed, we identified 223 proteins with 
at least >1.2-fold decrease in protein levels after combination 
treatment, of which 47 proteins exhibited statistically signifi-
cant reductions (P < 0.05; Fig. 5 B). Among these 47 potential 
CMA substrates, there was a significant enrichment (48%) of 
proteins containing one or more pentapeptide motifs that are 
biochemically related to the CMA-targeting motif (KFERQ). 
The CMA-targeting motif is degenerate and allows a series of 
amino acid combinations (Cuervo, 2010), and, consistently, an 
analysis with relaxed stringency revealed that almost 79% of all 
statistically decreased proteins had potential a CMA targeting 
motif, including p53 and Hsc70, which have been previously 
reported as bona fide CMA substrates (Fig. 5 B and Table S1).
We verified a subset of this CMA-degradome, including 
FAM3C, STG1 (hECD), and HK2, which showed a time-depen-
dent reduction upon treatment with a combination of AC220 and 
C43 (Fig. 5 C). Pretreatment with ClQ, a lysosomal inhibitor, sig-
nificantly attenuated FAM3C, STG1, and HK2 degradation under 
the same conditions, whereas the proteasome inhibitor MG132 
showed no effect (Fig. 5 D). These results are similar to known 
CMA substrates such as GAPDH and mutant p53 (Figs. 5 A and 
3 D). Of particular interest to this study were the potential CMA 
substrates that might be involved in the metabolism and survival 
of cancer cells. We directed our focus on HK2, a key mediator of 
metabolism often overexpressed in cancer cells (Wolf et al., 2011; 
Dey et al., 2012; Patra et al., 2013) and found to be degraded after 
inhibition of tripeptidyl peptidase II (TPPII), which leads to acti-
vation of lysosomal degradation (Lu et al., 2014). No decrease in 
the mRNA levels of HK2 was found after combination treatment 
with C43 and AC220 (Fig. S3 E), which verifies that the reduc-
tion in the levels of HK2 is due to an increase in degradation. The 
degradation of HK2 levels was also confirmed using Sum159 
cells upon treatment of AC220 and C43 (Fig. S3 F).
HK2 is known as an oncogenic kinase that promotes multiple 
metabolic pathways that are essential to prevent metabolic stress. 
HK2 overexpression helps cancer cells maintain growth factor–in-
in glucose levels in the culture medium of ES2 cells treated with AC220 and/or C43 (normalized to cell numbers) for 16 h. (D and E) The glycolytic activity 
and maximum glycolytic capacity of ES2 (D) or Molm-14 (E) cells, determined by ECAR, after AC220 and C43 treatment for 12 h (ES2) or 8 h (Molm-14). 
(F) Glucose flux analysis using [U13C]glucose. A schematic depiction of intermediary metabolites of glycolysis is shown. 13C enrichment of intracellular 
glucose-derived metabolites, marked in bold, is presented. (G) WB of LC3 protein levels in ES2 cells, treated with increasing concentrations of AC220 and/
or 5 µM E64D for 16 h (top), or treated with C43 or A70 in combination with AC220 and/or 5 µM E64D for 24 h. Anti–α-tubulin was used as a loading 
control. Cells were treated with 0.1% DMSO (control: vehicle), 1 µM AC220, 10 µM C43, or 1 µM A70, unless otherwise stated. In all the experiments, 
treatment groups were compared with the control group, unless otherwise shown. Error bars indicate ±SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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dependent glucose metabolism to suppress cell death after growth 
factor withdrawal (Mason et al., 2010); thus, its degradation by 
CMA might be causal to the observed metabolic malfunction upon 
combination treatment. We postulated that HK2 degradation upon 
combination treatment, when glycolysis is blocked, might lead to 
metabolic catastrophe and cell death. Consistently, knockdown of 
HK2, but not of p53, SGT1, or FAM3C, in ES2 cells significantly 
induced cell death (Fig. 5 E and S3 G), confirming that the loss of 
HK2 alone is sufficient to induce cell death.
Interestingly, the potential CMA-targeting motif we iden-
tified in HK2 is 712QRFEK716, a stringent CMA motif, and is 
involved in direct binding to glucose molecules (Fig. 5 F; Mu-
Figure 3. Combination treatment of AC220 and spautins induces CMA. (A) WB quantification of mutant p53 levels in ES2 (top) for the indicated time points 
and in MDA-MB-231, Sum159, and MDA-MB-435 (bottom) cells treated with AC220 and/or C43 for 16 h. (B) Mutant p53 levels in scramble (SCR) or FLT3 
siRNA–transfected ES2 cells treated with C43 for 24 h. This experiment used the same blot as that in Fig. 1 E with additional antibodies. (C) p53 levels in ES2 
cells treated with C43 and AC220 for 24 h in the absence or presence of proteasome (MG132) or lysosomal inhibitor (ClQ). (D) p53, IκB, and GAPDH levels 
in ES2 and Sum159 cells treated with AC220 and/or C43 for the indicated time points. (E) WB of p53, Lamp2A, and Hsc70 levels in nontargeting (N.T.), 
Hsc70, or Lamp2A siRNA–transfected ES2 cells treated with AC220 and/or C43 for 24 h. (F) The cellular ATP levels (fold) in ES2 cells treated with AC220 
and/or C43 in the presence or absence of zVAD or 7N-1 for 16 h. (G) Cell death indicated as Annexin V/PI positivity (fold) and WB of PARP-1 and caspase-3 
cleavage in ES2 cells treated with AC220 and/or C43 in the presence or absence of zVAD or 7N-1 for 24 h. STS was used as a positive cell death inducer. 
(H) Cell death (fold) of nontargeting (N.T.), Lamp2A, or Hsc70 siRNA–transfected ES2 cells treated with AC220 and/or C43 for 24 h. Anti–α-tubulin was used 
as a loading control. Cells were treated with 0.1% DMSO (control: vehicle) or 1 µM AC220 and 10 µM C43, unless otherwise stated. In all the experiments, 
treatment groups were compared with the control group, unless otherwise indicated. Error bars indicate ±SD. *, P < 0.05; **, P < 0.01.
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lichak et al., 1998). In the presence of glucose, the CMA motif 
is buried in the structure after being bound to glucose. In the 
absence of glucose, the CMA motif of HK2 is likely exposed, 
accessible to recognition and binding with Hsc70, and thereby 
Lamp2A. Accordingly, upon C43 and AC220 treatment, when 
cellular glucose levels are extremely low, the binding of HK2 
with both Hsc70 and Lamp2A is enhanced as shown by coim-
munoprecipitation experiments (Fig.  5  F). Consistently, treat-
ment of cells with 2-deoxy-d-glucose (2DG), which completely 
inhibits glucose metabolism, leads to HK2 degradation and cell 
death in combination with C43 (Fig. S3 H). Furthermore, siRNA- 
mediated knockdown of either Hsc70 or Lamp2A before the 
combination treatment rescued HK2 depletion (Fig.  5  G and 
S3 I), which suggests that the degradation of HK2 is mediated 
through the activation of the CMA pathway.
To verify the degradation of HK2 in the lysosomes, we iso-
lated lysosomal fractions of cells treated with C43 and AC220. 
After combination treatment, the lysosomal fractions of ES2 cells 
showed a marked enrichment of HK2 (Fig. 5 H), showing the ly-
sosomal targeting of HK2 upon CMA activation. To functionally 
Figure 4. Combination treatment of AC220 and spautins induces metabolic catastrophe. (A) The cellular ATP levels (fold) in scramble (SCR), Lamp2A, or 
Hsc70 siRNA–transfected ES2 cells treated with AC220 and/or C43 for 16 h (C43). WB shows the Hsc70 and Lamp2A siRNA knockdown efficiencies. 
(B) The intracellular ATP content and ADP/ATP ratio of ES2 cells treated with AC220 and/or C43 for 12 h. (C) Relative change in the NAD+/NADH ratio 
in lysates from ES2 cells treated with AC220 and/or C43 for 12 h. (D) The rate of mitochondrial respiration measured by OCR in ES2 cells treated with 
AC220 and/or C43 for 8 h. (E) Relative change in glutamine levels in the culture medium of ES2 cells treated with AC220 and/or C43 (normalized to 
cell numbers) for 16 h. (F) The cellular ATP levels in ES2 treated with AC220 and/or C43 in the absence or presence of Oligomycin, Rotenone, Etomoxir, 
or T0070907 for 16 h. (G) ATP-coupled OCR in scramble (SCR), Hsc70, or Lamp2A siRNA–transfected ES2 treated with AC220 and/or C43 for 8 h.  
Anti–α-tubulin was used as a loading control. Cells were treated with 0.1% DMSO (control: vehicle) or 1 µM AC220 and 10 µM C43, unless otherwise 
stated. In all the experiments, treatment groups were compared with the control group, unless otherwise shown. Error bars indicate ±SD. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001.
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Figure 5. Degradation of HK2 via CMA leads to metabolic stress and cell death. (A) Mutant p53 levels in the cytosolic fraction of ES2 cells treated with 
AC220 and for 16 h in the absence or presence of MG132. (B) Scatter plot depicting proteins identified and quantified in a quantitative proteomics 
experiment. Proteins significantly enriched as containing one or more stringent or loose motif biochemically related to KFERQ are highlighted as potential 
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determine the importance of the identified 712QRFEK716 motif in 
HK2 for its degradation induced by the combination treatment, 
we generated an HK2 mutant (Q712A;R713A) with a two-ami-
no-acid mutation in its CMA motif 712AAFEK716. We found that 
the binding of Q712A;R713A mutant HK2 protein with Hsc70 in 
293T cells with combination treatment was significantly reduced 
(Fig. 5 I). The degradation of Q712A;R713A mutant HK2 in ES2 
cells treated with C43 and AC220 was markedly repressed com-
pared with that of wild-type (wt) HK2 (Fig. 5 J, top). Finally, we 
found that the gain of function of the CMA-resistant HK2 mutant 
was to rescue the observed ATP drop and cell death effects induced 
by the combination treatment of AC220 and C43 (Fig. 5 J, bottom). 
From these results, we conclude that HK2 is a CMA substrate with 
a canonical CMA motif whose accessibility is regulated by the 
presence of glucose and that the degradation of HK2 through CMA 
may lead to metabolic catastrophe and cell death.
Our study suggests that the degradation of metabolic pro-
teins through the activation of the CMA pathway might directly 
connect metabolic malfunction/collapse to cell death, providing 
a molecular link between metabolic stress and cell death. In ad-
dition, because HK2 is known to be tightly associated with the 
mitochondrial membrane via interaction with the mitochondrial 
voltage-dependent anion channel (Kroemer and Pouyssegur, 
2008), the loss of HK2 might not only block glucose metab-
olism but also directly impair the health of mitochondria. We 
propose that pharmacological manipulation of the FLT3 path-
way and autophagy may lead to the activation of CMA pathway 
in cancer cells and a mechanism to promote cancer cell death, 
even of those that have acquired mutations to overcome intrinsic 
apoptosis, through metabolic catastrophe. Our results support 
the proposal of a model in which CMA may be exploited as a 
method to eliminate cancer cells by activating the degradation of 
the pro-oncogenic proteins, such as HK2. The ability of CMA 
to promote the degradation of HK2 and mutant p53 suggests the 
potential utility of CMA in manipulating cellular metabolism as 
a means of novel anticancer therapeutics.
Materials and methods
Cell lines and culture conditions
Cell lines were cultured as described previously (Liu et al., 2011; Va-
kifahmetoglu-Norberg et al., 2013). The AML, HEL, OCI-AML3, and 
Molm-14 cell lines were cultured in RPMI (10% FBS and 1% penicil-
lin/streptomycin). For glucose-free conditions, cell culture media with 
no glucose was supplemented with dialyzed FBS. Cells were treated 
in nonconfluent condition (∼60% confluence) or in contact-inhibited 
100% confluent condition. Cell proliferation measurement was per-
formed using the BrdU Cell Proliferation Assay kit (Cell Signaling 
Technology) according to the manufacturer’s protocol.
Chemical compounds and treatments
C43 (10 µM), AC220 (1 µM), or A70 (1 µM) were used unless other-
wise stated. STS (1 µM), MG132 (10 µM), ClQ (50 µM), LY294002 
(10 µM), GDC-0941 (0.5 µM), MK2206 (1 µM), oligomycin (0.1 µM), 
Rotenone (0.1  µM), Etomoxir (5  µM), T0070907 (5  µM), d-glucose 
(11 mM), 2DG (1, 2 or 5 mM), zVAD.fmk (20 µM), 7N-1 (20 µM), 
and doxorubicin (1.25 µg/ml) were also used. DMSO (0.1%) was 
used as a control. Cell viability and ATP levels were measured using a 
CellTiterGlo ATP assay (Promega). The ADP/ATP and NAD+/NAHD 
ratios were determined with assay kits (Abcam) according to the man-
ufacturer’s instructions. Annexin V/PI staining was detected by using 
a flow cytometer using an FITC Annexin V Apoptosis Detection kit I 
(BD). Cell death/survival was measured using the ToxiLight bioassay 
(Thermo Fisher Scientific). Cellular fractionation was performed using 
differential centrifugation and hypotonic lysis of lysosomes, accord-
ing to Schröter et al. (1999). Coimmunoprecipitation was performed 
using RIPA buffer and 1 µg antibody per sample incubated with A/G for 
2 h. For genetic knockdown experiments, scramble (SCR)/nontarget-
ing (N.T) or siRNA targeting ATG7 (GE Healthcare) Lamp2A, Hsc70 
(GE Healthcare), FLT3 (Santa Cruz Biotechnology, Inc.), or HK2, p53, 
SGT1, and FAM3C (GenePharma) were used at 40 nM. siRNA effi-
ciency was monitored 48–72 h after transfection.
Small molecule compound screen
ES2 cells seeded in nonconfluent conditions in a 384-well plate were 
exposed to 8,248 small molecules from the ICCB known bioactive 
chemical library. A70 was used at 100 nM. For all plates, doxorubicin 
[1.25 µg/ml] was used as a positive control for cell death. Plates were 
screened in duplicate. After 30 h of treatment time, the CellTiter-Glo 
Luminescent Cell Viability assay was performed. Possible hits were 
based on z scores calculated using the formula Z = (X − Ave_Neg)/
SD_Neg or 25% of difference in cell survival between library alone and 
in combination with A70. 115 compounds were identified and cher-
ry-picked for a secondary screen.
Cellular metabolic measurements
ECAR and OCR were measured in real time using the Seahorse XFp 
analyzer instrument according to the Seahorse standard protocols: XFp 
Glycolysis Stress Test kit (http://www.seahorsebio.com/resources/
pdfs/manual-xf96-glycolysis-stress-test-kit.pdf) and XFp Cell Mito 
Stress Test kit (http://www.seahorsebio.com/resources/pdfs/manual-
xf24-cell-mito-stress-test-kit.pdf).
Glucose and lactate were measured in spent medium using a 
multiparameter bioanalytical system (YSI 7100; Yellow Springs Instru-
ments). Glucose uptake is presented as the net decrease in concentra-
CMA substrates. (C) HK2, SGT1, and FAM3C protein levels in ES2 cells treated with AC220 and C43 up to 24 h. (D) WB analysis of HK2, SGT1, FAM3C, 
p53, and GAPDH levels in ES2 cells treated with AC220 and C43 for 16 h in the absence or presence of proteasome (MG132) or lysosomal inhibitor 
(ClQ). This experiment (bottom row) used the same blot as in the bottom row of Fig. 3 C with additional antibodies. (E) Cell viability (%) and cell death 
(fold) of scramble (SCR) or HK2 siRNA–transfected ES2 cells at 72 h after transfection. (F) The combined ribbon representation and stick model showing 
the overall structure and the CMA motif of HK2 protein in complex with glucose. The interaction of HK2 with Hsc70 or Lamp2A, after AC220 and/or 
C43 treatment, was analyzed by coimmunoprecipitation. (G) WB of HK2, p53, and GAPDH levels in ES2 cells transfected with nontargeting (N.T) or 
Hsc70 siRNA, treated with AC220 and C43 for 12 h. (H) The localization of HK2 in cellular endosomal/mitochondria (EM), lysosomal (L), or cytosolic (C) 
fractions in ES2 cells treated with AC220 and C43 for 16 h, in the presence of the lysosomal inhibitor (ClQ). Lamp2A, Tom40, or β-actin were used as 
markers for the fractions. (I) The interaction of wt or Q712A;R713A mutant GFP-HK2 with Hsc70, after AC220 and/or C43 treatment, analyzed in 293T 
cells by coimmunoprecipitation. (J) WB analysis, cell viability (%), and cell death (fold) of wt and Q712A;R713A mutant GPF-HK2–expressing ES2 cells 
after AC220 and C43 treatment for 16 h. Anti–α-tubulin was used as a loading control. Cells were treated with 0.1% DMSO (control: vehicle) or 1 µM 
AC220 and 10 µM C43, unless otherwise stated. In all the experiments, treatment groups were compared with the control group, unless otherwise shown. 
Error bars indicate ±SD. ***, P < 0.001.
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tion, and lactate production as the net increase in concentration after 
normalization to cell numbers.
Metabolite extraction and flux analysis
ES2 cell samples treated for 8 h were incubated with [U13C6] glucose and 
DMSO, 1 µM AC220, 10 µM C43, and 1 µM AC220 + 10 µM C43 for an 
additional 6 h. Metabolites were extracted using MeOH/ACN/H2O (2:2:1, 
vol/vol). The extracts were reconstituted in ACN/H2O (1:1, vol/vol), in-
soluble debris were removed, and extracts were transferred to HPLC 
vials for liquid chromatography–mass spectrometry (LC-MS) analysis. 
The LC-MS analysis was performed using a UPLC system (1290 series; 
Agilent Technologies) coupled to a Q-TOF mass spectrometer (Agilent 
6550 iFunnel Q-TOF LC-MS; Agilent Technologies) for the analyses.
Protein digestion and TMT labeling for mass spectrometry  
and LC-MS/MS
Three biological replicates of lysates of ES2 cells treated with C43 
and AC220 for 16  h (MG132 for the last 4  h) were precipitated by 
methanol/chloroform, and protein samples were resuspended in 8 M 
urea/100 mM TEAB, pH 8.0, and reduced, then alkylated with 10 mM 
Tris (2-carboxyethyl) phosphine hydrochloride and 55 mM iodoacet-
amide, followed by tryosin digestion. The resultant peptides were la-
beled with 6-plex TMT reagents as the user manual describes (Thermo 
Fisher Scientific). The resulted 6-plex mixture of peptides was analyzed 
on a hybrid LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher 
Scientific) using a modified 12-step MudPIT separation that has been 
described previously (Washburn et al., 2001; Rauniyar et al., 2015). 
Application of ms scan functions and HPLC solvent gradients were 
controlled with the Xcalibur data system (Thermo Fisher Scientific).
Data analysis
Data were extracted from the Xcalibur data system format into MS1 and 
MS2 formats using in-house software. The peptides/proteins were iden-
tified by the Integrated Proteomics Pipeline-IP2 software (Integrated 
Proteomics Applications, http://www.integratedproteomics.com/) using 
ProLuCID and DTASelect2 (Tabb et al., 2002) with a decoy database 
strategy. The precursor mass tolerance was 50 ppm and the fragment 
mass tolerance was 20 ppm. The precursor delta mass cutoff was 10 ppm 
in DTASelect. The searches were against Uniprot Human protein data-
base (version 07-05-2014). The ratios of treated versus control samples 
were calculated to normalized protein intensities. A sample difference 
of P < 0.05 was considered statistically significant (Student’s t test). The 
stringent ([Q/N][K/R][F/I/V/L][E/D][K/R], [K/R][F/I/V/L][E/D][K/R]
[Q/N]) and relaxed ([Q/N/V][D/E/K/R/F][E/K/V/L][D/E/K/R/V/F/L]
[D/E/Q]) CMA motifs were designed based on Kaushik and Cuervo 
(2012) using MotifGen software (http://www.proteinguru.com/toolbox/
motifgen/). Protein sequences were batch retrieved from Uniprot (ver-
sion 07-05-2014, http://www.uniprot.org/) and CMA motif searches 
were performed using the regular expression search engine BASALT 
(http://www.proteinguru.com/toolbox/basalt/).
Autophagy index analysis
Image analysis of H4-GFP-LC3 cells fixed with 4% paraformaldehyde 
(Sigma-Aldrich) and stained with 3 µg/ml DAPI (Sigma-Aldrich), 
using ArrayScan HCS 4.0 Reader with a 20× objective lens (Cellomics 
ArrayScan VTI; Life Technologies). The Spot Detector BioApplication 
(Thermo Fisher Scientific) was used to acquire and analyze the images 
after optimization. Images of 1,000 cells for each compound treatment 
were analyzed to obtain the mean cell number per field, fluorescence 
spot number, area, and intensity per cell. DMSO and rapamycin were 
used as negative or positive controls, respectively. The percentages of 
changes of LC3-GFP were calculated by dividing with that of DMSO- 
treated samples. The images were also analyzed by using a conven-
tional fluorescence microscope for visual inspection. The experiments 
were repeated three times with consistent results.
Site-directed mutagenesis
A site-directed mutagenesis kit (F-541; Thermo Fisher Scien-
tific) was used to generate the Q712A;R713A mutant gene and 
the mutation was verified by DNA sequencing. Mutagenesis 
primers were designed using QuikChange Primer Design soft-
ware (www.genomics.agilent.com/primerDesignProgram.jsp): 
HK2_Q739A+R740A_sense, 5′-CTTTCACTCAACCCCGGCAA-
GGCGGCGTTCGAGAAAATGATCAGTGG-3′; and 
HK2_Q739A+R740A_anti-sense, 5′-CCACTGATCATTTTCTC-
GAACGCCGCCTTGCCGGGGTTGAGTGAAAG-3′.
Real-time quantitative PCR
RNA was isolated using an RNA isolation RNAqueous kit (Ambion). 
Reverse-transcribed cDNAs from the samples were used as templates 
(using Maxima First Strand cDNA synthesis Kit for RT-qPCR). cDNA 
template was mixed with Maxima SYBR Green qPCR Master Mix 
(Thermo Fisher Scientific) and amplified using a 7500 Real-Time PCR 
System (Applied Biosystems) with the following primers: HK2 forward, 
5′-CAAAGTGACAGTGGGTGTGG-3′; HK2 reverse, 5′-GCCAG-
GTCCTTCACTGTCTC-3′; p53 forward, 5′-GTTCCGAGAGCT-
GAATGAGG-3′; p53 reverse, 5′-TTATGGCGGGAGGTAGACTG-3′; 
β-actin forward, 5′-GCAAGCAGGAGTATGACGAG-3′; and β-actin 
reverse, 5′-CAAATAAAGCCATGCCAATC-3′.
Statistical analyses
All graphs were analyzed using GraphPad Prism 6 software. Quanti-
tative data represented by bar graphs from at least three independent 
experiments, in triplicate, are shown and expressed as mean ± SD fol-
lowed by the analysis of variance (Vaux, 2012). Some data are pre-
sented as fold change over control (DMSO). In all the experiments, 
treatment groups were compared with the control group, unless other-
wise shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Antibodies used
Primary antibodies used were as follows: anti-p53 (#2524; Cell Sig-
naling Technology), anti-USP10 (ab72486; Abcam), anti-USP13 
(16840-1-AP; ProteinTech), anti-BECN1 (H-300, sc-11427; Santa Cruz 
Biotechnology, Inc.), anti-tubulin (T8203; Sigma-Aldrich), anti-FLT3 
(#3462; Cell Signaling Technology), anti–p-FLT3 (#3466; Cell Signal-
ing Technology), anti-Lamp2A (sc-18822; Santa Cruz Biotechnology, 
Inc.), anti-Hsc70 (HSPA8; 10654-1-AP; Proteintech), anti-Akt (#9272; 
Cell Signaling Technology), anti-p-Akt (#9271; Cell Signaling Technol-
ogy), anti-LC3 (L7543; Sigma-Aldrich), anti-PARP (556494; BD), anti–
cleaved caspase-3 (#9661; Cell Signaling Technology), anti-GAPDH 
(sc-166545; Santa Cruz Biotechnology, Inc.), anti-Erk (#9102; Cell Sig-
naling Technology), anti-p-Erk (#9101; Cell Signaling Technology), an-
ti-IκB (sc-371; Santa Cruz Biotechnology, Inc.), anti-HK2 (#2867; Cell 
Signaling Technology), anti-SGT1 (ab99293; Abcam), anti-FAM3C 
(ab56065; Abcam), anti-Tom40 (sc-11414; Santa Cruz Biotechnology, 
Inc.), and anti-actin (sc-81178; Santa Cruz Biotechnology, Inc.). Quan-
tifications of the WBs are provided in Tables S2 and S3.
Online supplemental material
Fig. S1 shows the structure of A70, the autophagy index in response 
to A70, and data relevant to single or combination treatment of C43, 
A70, or AC220 in different culture conditions, as well as phospho- and 
total FLT3 protein levels of all cell lines tested in the study. In addi-
tion, cell viability of cancer cells treated with Lapatinib or Nilotinib are 
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presented. Fig. S2 shows additional data relevant to metabolic changes 
as well as phospho-, total FLT3, and LC3 protein levels of cancer 
cell lines treated with AC220, C43, and other indicated inhibitors. In 
addition, cell death and LC3 protein levels of ES2 cells treated with 
AC220, MK2206, or GDC-0941 are presented. Fig. S3 shows data on 
mRNA and protein levels of mutant p53, HK2 in cancer cells treated 
with AC220, and/or C43 in the absence or presence of proteasome or 
lysosomal inhibitors. The protein levels of HK2, p53, and GAPDH 
after Lamp2A knockdown in ES2 cells treated with AC220 and C43 
are also presented. In addition, cellular ATP levels are shown after 
Hsc70 knockdown with AC220 and/or C43 treatment in the absence 
or presence of oligomycin. Further, cell viability of HK2, p53, SGT1, 
or FAM3C knockdown ES2 cells treated with AC220 and/or C43 as 
well as ES2 cells treated with 2DG and/or C43 are presented. Table S1 
shows a list of proteins identified in quantitative proteomics approach. 
Table S2 and Table S3 show all WB quantifications presented in the 
main and supplemental figures. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201503044/DC1.
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